TV News LIES

Wednesday, Jul 02nd

Last update06:57:18 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


How Trump's tax bill could cut Medicaid for millions of Americans

Thealth insurancehe Senate cleared President Donald Trump's domestic spending and tax cut bill that will enact steep...

As new variant spreads, what's the latest COVID-19 vaccine guidance? It's complicated.

New vaiantAs a new COVID-19 variant takes over in the U.S., guidance surrounding vaccines has become increasingly...

Supreme Court rejects censorship case from RFK Jr.'s anti-vaccine group

RFK Jr. The Supreme Court on June 30 declined to to hear a censorship complaint brought by Health...

RFK Jr. says U.S. will stop funding global vaccine group over 'vaccine safety' issues

RFK Jr.The international vaccine agency, Gavi, has strongly rejected HHS Secretary Kennedy's accusations that it was not...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!